ArticleSurgical neurology international2026
Neuroprotective potential of asprosin in traumatic brain ınjury: Histopathological and biochemical insights from an experimental rat model.
Article in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Traumatic brain injury (TBI) remains a leading cause of morbidity and mortality, yet pharmacological neuroprotection is still an unmet need. Asprosin, a recently identified fasting-induced adipokine, has been implicated in oxidative stress modulation, apoptosis, and metabolic regulation. This study aimed to investigate the neuroprotective role of asprosin in an experimental rat model of TBI. Methods: Thirty-two male Wistar rats were randomized into four groups: Control, Trauma, Trauma+Asprosin, and Asprosin. Moderate head trauma was induced using a validated closed-head injury model. Asprosin (10 µg/kg, intraperitoneal) was administered immediately and 12 h post-trauma. Brain tissues were examined histopathologically (cresyl violet staining) and biochemically for oxidative stress and apoptotic markers, including Glutathione, total oxidant status, superoxide dismutase, Catalase, Malondialdehyde, glutathione peroxidase, nitric oxide, total antioxidant status, asprosin, and caspase-3. Results: Histopathological evaluation revealed pronounced neuronal degeneration, vacuolization, and darkly stained nuclei in the Trauma and Trauma+Asprosin groups, whereas the control and asprosin-only groups preserved normal cortical and hippocampal architecture. Biochemically, no significant differences were observed among groups for oxidative stress parameters; however, caspase-3 levels were significantly higher in the Asprosin group compared to controls ( Conclusion: This study provides the first experimental evidence linking asprosin to TBI. Although asprosin demonstrated potential interactions with oxidative and apoptotic processes, its role as a neuroprotective agent requires further validation with larger cohorts, varied dosing regimens, and molecular analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.